Modelling the health, financial protection and equity impacts of upscaling the ACT NOW early intervention breast cancer pilot program in the Philippines: an extended cost-effectiveness analysis (3 ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

The heartwarming update comes just weeks after Gerrard's daughter Lilly-Ella shared the news that she's expecting her first child. The former Liverpool captain, who often gives fans a glimpse into ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Lilly Gerrard, 20, has recently shared the exciting ... time for his involvement in a botched weapons plot and is now under house arrest after serving three months of a five-year sentence.

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...